Eli Lilly Leads Five Stocks Near Buy Points In Divided Market

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle.

Investors Business Daily • Dec 13, 2025

Eli Lilly: The Right Long-Term Strategy

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying competition and looming patent expirations, but is proactively expanding into oral, triple-agonist, and novel biologic modalities to sustain long-term revenue. Valuation risk is high in the near term, yet the robust pipeline support a buy rating for long-term investors.

Seeking Alpha • Dec 13, 2025

My Top 10 Stocks to Buy for 2026

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.

The Motley Fool • Dec 13, 2025

My Top 3 Healthcare Stocks to Buy in 2026

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas.

The Motley Fool • 20 hours ago

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.

24/7 Wall Street • Dec 12, 2025

Think Eli Lilly Is Expensive? This Metric Says Otherwise.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels.

The Motley Fool • Dec 12, 2025

Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10

On Friday, Europe's drug regulator recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.

Investors Business Daily • Dec 12, 2025

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

Zacks Investment Research • Dec 12, 2025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a year These data were published simultaneously in Annals of Oncology and will be presented today at the 2025 San Antonio Breast Cancer Symposium INDIANAPOLIS , Dec. 12, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy, imlunestrant demonstrated a clinically meaningful 38% reduction in the risk of progression or death (median PFS 5.5 vs 3.8 months; HR=0.62 [95% CI 0.47–0.82]; nominal p=0.0007) and demonstrated an 11.4-month improvement in median OS (34.5 vs 23.1 months; HR=0.60 [95% CI 0.43–0.86]; p=0.0043; boundary for significance not met) versus endocrine therapy, in patients with ESR1-mutated disease.

PRNewsWire • Dec 12, 2025

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Zacks Investment Research • Dec 12, 2025